20 completed, 17 terminated, 5 active not recruiting, 4 withdrawn. 35 Phase 2, 24 Phase 1, 2 Phase 3.
Follow itacitinib: new trials by email Literature Review of itacitinib trials Research Report on itacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-05-19 | 2026-09-16 |
| Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Itacitinib, Corticosteroid, Endoscopic Procedure - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Withdrawn | Douglas Johnson | 2023-03-03 | 2026-04-27 | |
| Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis Itacitinib, Placebo - Systemic Sclerosis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 74 | 2023-02-02 | 2025-11-20 |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2022-12-29 | 2026-10-14 |
| Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB Itacitinib - Adults Patients Having Non Severe HLH | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 35 | 2022-05-03 | 2025-12-26 |
| Itacitinib for the Prevention of Graft Versus Host Disease Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematologic and Lymphocytic Disorder | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2022-01-11 | 2026-10-07 |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) ASTX727, Itacitinib, Ruxolitinib - MDS/MPN | Phase 1 / Phase 2 | Recruiting | Michael Savona | 94 | 2021-11-24 | 2026-04-21 |
| Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Itacitinib, Itacitinib Adipate - Bronchiolitis Obliterans | Phase 1 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-10-08 | 2025-11-10 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) itacitinib - Myelofibrosis, Polycythemia Vera | Phase 2 | Completed | Incyte Corporation | 4 | 2021-07-12 | 2025-09-02 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine - Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-09-22 | 2020-10-29 | |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib - B-Cell Malignancies | Phase 2 | Active not recruiting | Incyte Corporation | 112 | 2020-08-03 | 2026-06-25 |
| A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease Itacitinib, Prednisone, Methylprednisolone - GVHD,Acute | Phase 1 / Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 1 | 2020-06-18 | 2020-10-29 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Itacitinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | SCRI Development Innovations, LLC | 15 | 2020-06-05 | 2024-11-06 |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Itacitinib, Immune effector cell therapy, Placebo - Cytokine Release Syndrome | Phase 2 | Completed | Incyte Corporation | 112 | 2020-02-07 | 2024-03-26 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease Itacitinib, Tocilizumab - Steroid Refractory GVHD, Graft Vs Host Disease | Phase 1 | Terminated | Columbia University | 1 | 2020-01-20 | 2024-06-04 |
Showing 20 of 51. Sign in to see all of them.
Graft vs Host Disease (6) · Myeloproliferative Disorders (6) · Bronchiolitis Obliterans Syndrome (5) · Carcinoma, Non-Small-Cell Lung (5) · Primary Myelofibrosis (5) · Hematologic Neoplasms (4) · Hodgkin Disease (3) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Breast Neoplasms (2) · Bronchiolitis Obliterans (2) · Hematologic Diseases (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Leukemia, Prolymphocytic, T-Cell (2)
Incyte Corporation (28) · M.D. Anderson Cancer Center (4) · Assistance Publique - Hôpitaux de Paris (2) · University of Pennsylvania (2) · City of Hope Medical Center (1) · Columbia University (1) · Douglas Johnson (1) · Fondazione per la Medicina Personalizzata (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Imperial College London (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · John Levine (1) · Massachusetts General Hospital (1) · Michael Savona (1)
United States (41) · Italy (8) · Spain (8) · France (7) · Austria (6) · Belgium (6) · Canada (5) · Germany (5) · United Kingdom (5) · Israel (4) · Poland (4) · Greece (3) · South Korea (3) · Australia (2) · Czechia (2)
Rodica Morariu-Zamfir, MD (6) · Peter Langmuir, MD (4) · Lance Leopold, MD (2) · Peter Langmuir (2) · Victor Sandor, MD (2) · Albert Assad, M.D. (1) · Albert Assad, MD (1) · Amin Alousi, MD (1) · Amit Pande, M.D. (1) · Andrea Botticelli (1) · Benjamin Chaigne, MD (1) · Catherine Lee, MD (1) · Claudia Corrado, M.D. (1) · Corey Langer, MD (1) · David M. Miller, MD, PhD (1)
PMID 35689489, PMID 15466922, PMID 15661029, PMID 20049711, PMID 22869151, PMID 27222478, PMID 27789678, PMID 29695516, PMID 30115734, PMID 30803990, PMID 32324888, PMID 32998963, PMID 34971577, PMID 35288468, PMID 36095841, PMID 38115208, PMID 39576962, PMID 40090005, PMID 41023484, PMID 41536780, PMID 41963505
2017 (5), 2018 (3), 2019 (3), K12CA167540 (1), P30CA033572 (1)